SBIR/STTR Research Award

Molecular Screens for Deubiquitinase Function

Award identifier 43e3b24c1c73773817946cd05c5fd6e2bf3cb2c3e0c89279109b33905282a501Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$363,348

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PROGENRA INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Z3JKMHXHFHJ6
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): A key aspect of cellular regulation that affords a number of potential opportunities for pharmacological intervention is the maintenance of protein homeostasis. Proteins are continuously being synthesized and degraded in cells, and their cellular levels must be strictly regulated. The ubiquitin-proteasome pathway is the major non-lysosomal proteolytic system in eucaryotic cells, consisting of a multi-enzyme cascade that modifies and degrades a diverse array of proteins, including many key regulatory molecules. The modification of cellular proteins by ubiquitin (Ub) and ubiquitin-like proteins (UBL) plays an essential role in a number of biological processes, including cell cycle control, transcriptional activation, signal transduction, antigen presentation, vesicular trafficking, and intracellular proteolysis. Ubiquitination is a dynamic reversible process, with a multitude of ubiquitin ligases (E3s) and deubiquitinases (DUBs) responsible for both the wide-ranging influence of this pathway as well as its selectivity. The DUB enzymes are responsible for maintaining adequate pools of free Ub within the cell and for regulating the ubiquitination status of cellular proteins. Defects in these enzymes appear to play a role in the pathogenesis of several diseases, including Parkinson's disease, Angelman's syndrome, cervical cancer, and von Hippel Lindau syndrome. This research proposal focuses on the DUBs and on the development of a novel high-throughput assay to identify agents that modulate the activity of these key regulatory enzymes. The assay being proposed is based on the observation that certain proteins require a defined and free amino-terminal residue in order to be functional. Fusions between Ub/UBL and these proteins will serve as substrates that undergo activation upon DUB cleavage. This reaction will be optimized and adapted to a high-throughput format for eventual use in screens for inhibitors/activators of clinically relevant DUBs.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

53 SBIR/STTR records share this UEI (2003–2025). Reported award amounts total $22,552,905. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.